Ultragenyx Pharmaceutical Inc. (RARE)

NASDAQ: RARE · Real-Time Price · USD

25.21

-0.40 (-1.56%)

At close: Aug 31, 2026, 4:00 PM EDT

25.21

0.00 (0.00%)

Pre-market: Sep 1, 2026, 4:28 AM EDT

Ultragenyx Pharmaceutical Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	717	673	560	434	363.33	351.41
Revenue Growth	17.51%	20.18%	29.03%	19.45%	3.39%	29.66%
Cost of Revenue	866	859	775	693	734.11	513.16
Gross Profit	-149	-186	-215	-259	-370.78	-161.76
Selling, General & Admin	349	349	321	310	278.14	219.98
Operating Expenses	349	349	321	310	278.14	219.98
Operating Income	-498	-535	-536	-569	-648.92	-381.74
Interest Expense	-77	-62	-63	-66	-43.02	-29.42
Interest & Investment Income	23	25	37	27	11.07	1.93
Other Non Operating Income (Expenses)	-	1	-5	-1	-1.57	-1.69
EBT Excluding Unusual Items	-552	-571	-567	-609	-682.43	-410.92
Merger & Restructuring Charges	-30	-	-	-	-	-
Gain (Loss) on Sale of Investments	-	-	-	-	-19.3	-42.06
Pretax Income	-582	-571	-567	-609	-701.73	-452.98
Income Tax Expense	4	4	2	-2	5.7	1.04
Net Income	-586	-575	-569	-607	-707.42	-454.03
Net Income to Common	-586	-575	-569	-607	-707.42	-454.03
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	101	99	91	74	70	68
Shares Outstanding (Diluted)	101	99	91	74	70	68
Shares Change	4.21%	8.95%	23.13%	5.13%	3.13%	11.42%
EPS (Basic)	-5.83	-5.83	-6.29	-8.26	-10.12	-6.70
EPS (Diluted)	-5.83	-5.83	-6.29	-8.26	-10.12	-6.70
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-489	-472	-421	-519	-496.59	-411.79
Free Cash Flow Per Share	-4.86	-4.79	-4.65	-7.06	-7.10	-6.07
Gross Margin	-20.78%	-27.64%	-38.39%	-59.68%	-102.05%	-46.03%
Operating Margin	-69.46%	-79.50%	-95.71%	-131.11%	-178.60%	-108.63%
Profit Margin	-81.73%	-85.44%	-101.61%	-139.86%	-194.70%	-129.20%
Free Cash Flow Margin	-68.20%	-70.13%	-75.18%	-119.59%	-136.68%	-117.18%
EBITDA	-465	-500	-500	-543	-630.7	-368.5
EBITDA Margin	-64.85%	-74.29%	-89.29%	-125.11%	-173.59%	-104.86%
D&A For EBITDA	33	35	36	26	18.22	13.24
EBIT	-498	-535	-536	-569	-648.92	-381.74
EBIT Margin	-69.46%	-79.50%	-95.71%	-131.11%	-178.60%	-108.63%
Revenue as Reported	717	673	560	434	363.33	351.41

SEC Filings: 10-K · 10-Q